Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ahmed Elgehama. (2022) Selective obstruction of the mTORC2 complex by a naturally occurring cholestane saponin (OSW-1) for inhibiting prostate cancer cell growth. Journal of Asian Natural Products Research 24:7, pages 663-672.
Read now
Read now
Wael A Harb. (2015) Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options. Cancer Management and Research 7, pages 37-46.
Read now
Read now
Gloria Yang-Kolodji, Shannon M. Mumenthaler, Arjun Mehta, Lingyun Ji & Debu Tripathy. (2015) Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers 20:5, pages 313-322.
Read now
Read now
Articles from other publishers (8)
Udit Chaube, Rajdeep Dey, Suman Shaw, Bhumika D Patel & Hardik G Bhatt. (2022) Tetrahydroquinoline: an efficient scaffold as mTOR inhibitor for the treatment of lung cancer. Future Medicinal Chemistry 14:23, pages 1789-1809.
Crossref
Crossref
Caitlin E. Mills, Kartik Subramanian, Marc Hafner, Mario Niepel, Luca Gerosa, Mirra Chung, Chiara Victor, Benjamin Gaudio, Clarence Yapp, Ajit J. Nirmal, Nicholas Clark & Peter K. Sorger. (2022) Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop. Nature Communications 13:1.
Crossref
Crossref
Constanze Elfgen & Vesna Bjelic-Radisic. (2021) Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. Cancers 13:23, pages 5994.
Crossref
Crossref
Pamela R. Drullinsky & Sara A. Hurvitz. (2020) Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Research and Treatment 181:2, pages 233-248.
Crossref
Crossref
Denise Rageot, Florent Beaufils, Chiara Borsari, Alix Dall’Asen, Markus Neuburger, Paul Hebeisen & Matthias P. Wymann. (2019) Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. Organic Process Research & Development 23:11, pages 2416-2424.
Crossref
Crossref
Chiara Borsari, Denise Rageot, Alix Dall’Asen, Thomas Bohnacker, Anna Melone, Alexander M. Sele, Eileen Jackson, Jean-Baptiste Langlois, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann & Matthias P. Wymann. (2019) A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of Medicinal Chemistry 62:18, pages 8609-8630.
Crossref
Crossref
Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M. Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John Burke, Doriano Fabbro & Matthias P. Wymann. (2018) Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. Journal of Medicinal Chemistry 61:22, pages 10084-10105.
Crossref
Crossref
Brennan McCullar, Manjari Pandey, George Yaghmour, Felicia Hare, Kruti Patel, Matthew Stein, Rebecca Feldman, Jason C. Chandler & Michael G. Martin. (2016) Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Research and Treatment 158:1, pages 195-202.
Crossref
Crossref